In a significant legal ruling, Johnson & Johnson (J&J) has been ordered by a Delaware judge to pay over $1 billion to the former investors of Auris Health, a surgical robotics firm acquired by J&J in 2019. This verdict is the result of J&J’s failure to adhere to the terms of the merger agreement which stipulated that J&J would provide the necessary resources to Auris to assist it in reaching regulatory milestones essential for receiving additional payments totaling more than $1 billion.
When J&J acquired Auris for $3.4 billion, the agreement included potential extra payments of up to $2.35 billion, contingent upon achieving specific milestones related to Auris’ robotic surgery systems, the iPlatform and Monarch. Despite the ambitious nature of these milestones, the judge noted that Auris was initially on track to meet them, as the timelines for these achievements were agreed upon under the condition that J&J would exert commercially reasonable efforts considering the systems were deemed a ‘priority medical device’.
However, post-acquisition, J&J’s actions deviated significantly from these commitments. According to the judge’s findings, instead of propelling Auris’ iPlatform forward, J&J initiated ‘Project Manhattan’, a competitive analysis pitting iPlatform against J&J’s own Verb robot, which was failing to meet its developmental milestones. This internal competition deprived iPlatform of the focus and resources needed to pursue its regulatory milestones. This led to iPlatform serving more as a component supplier for Verb rather than being developed as a standalone system capable of reaching its market potential.
Additionally, J&J’s handling of the Monarch platform also came under scrutiny. The judge determined that J&J committed fraud that ultimately obstructed the achievement of a regulatory milestone for Monarch’s soft tissue ablation procedure, which was tied to a $100 million payment. J&J had reassured Auris that this milestone was almost guaranteed, not disclosing that ongoing FDA investigations into a J&J catheter supposed to be used with Monarch might impede progress.
The ruling underscores that J&J not only failed to provide the agreed-upon resources but also initiated strategies that were counterproductive to Auris achieving the agreed goals. The financial penalty imposed—more than $1 billion—reflects compensation for the milestone payments that Auris’ investors lost out on due to these actions. Furthermore, it highlights a considerable lost opportunity in terms of what Auris’ technology could have achieved if it had been properly supported post-merger.
J&J, on the other hand, disagrees with the court’s decision, arguing that the obligation imposed by the court was commercially unreasonable and contrary to the evidence presented. They intend to appeal against the ruling, maintaining that their interpretation of the merger agreement allowed them to leverage Auris’ products to support their broader robotics business ambitions rather than being strictly bound to achieve the specific milestones.
This case not only involves substantial financial implications but also casts a spotlight on the challenges and expectations tied to mergers and acquisitions, especially in high-stakes sectors like medical devices and technology. It underscores the importance of clear agreements and the faithful execution of stated commitments in merger deals, which, if neglected, can lead to significant legal and financial repercussions.
#Judge #orders #pay #Auris #investors #merger #violations
